Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. MU
4. META
5. SPY
6. ACN
7. NVDA
8. BLZE
9. IBM
10. PRIM

Go back to Medicus Pharma Initiates Groundbreaking PRECISION-E2 Phase 2a Study of Teverelix® in Endometriosis utilizing the Emirati Genome Program
(NASDAQ: MDCX) Delayed: 0.46 +0.01 (2.22%)
Previous Close $0.45    52 Week High $ 
Open $0.43    52 Week Low $ 
Day High $0.47    P/E N/A 
Day Low $0.43    EPS $ 
Volume 1,227,185       

(NASDAQ: MDCX) Delayed: 0.46 +0.01 (2.22%)
Previous Close $0.45    52 Week High $ 
Open $0.43    52 Week Low $ 
Day High $0.47    P/E N/A 
Day Low $0.43    EPS $ 
Volume 1,227,185